Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2017-04-03 DeSouza Warren L. Chief Financial Officer Sell 15,000 $21.58 $323,736 Yes
2017-03-21 DeSouza Warren L. Chief Financial Officer Sell 10,000 $22.95 $229,500 Yes
2016-11-11 Barrowcliffe Susan E. General Manager, Europe Sell 20,000 $25.00 $500,000 Yes
2016-11-11 DILLY STEPHEN GEORGE See Remarks Sell 50,000 $25.01 $1,250,590 No
2016-11-08 Barrowcliffe Susan E. General Manager, Europe Sell 15,000 $20.00 $300,000 Yes
2016-11-04 Rozenman Mary M. See Remarks Sell 24,096 $17.60 $424,090 Yes
2016-10-05 Rozenman Mary M. See Remarks Sell 25,000 $16.80 $420,000 Yes
2016-09-08 Rozenman Mary M. See Remarks Sell 30,000 $16.80 $504,000 Yes
2016-05-31 Foresite Capital Management II, LLC 10%-Owner Sell 240,000 $15.23 $3,654,720 No
2016-03-29 ENRIGHT PATRICK G 10%-Owner, Director Buy 78,504 $13.87 $1,089,135 No
2016-03-29 Longitude Capital Partners II, LLC 10%-Owner Buy 78,504 $13.87 $1,089,135 No
2015-08-24 Foresite Capital Management II, LLC 10%-Owner Buy 25,485 $19.65 $500,900 No
2015-08-11 Longitude Capital Partners II, LLC 10%-Owner Buy 312,500 $16.00 $5,000,000 Yes
2015-08-11 Foresite Capital Management II, LLC 10%-Owner Buy 642,035 $16.12 $10,349,199 Yes
2015-08-11 Iwicki Mark T Director Buy 20,000 $16.00 $320,000 No
2015-08-11 MCDADE MARK Director Buy 16,660 $16.00 $266,560 No
2015-08-11 FALBERG KATHRYN E Director Buy 25,000 $16.00 $400,000 No
2015-08-11 ENRIGHT PATRICK G 10%-Owner, Director Buy 312,500 $16.00 $5,000,000 Yes

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.